Sichuan Kelun-Biotech Reports Phase III Overall Survival Benefit in TNBC
The company said sacituzumab tirumotecan showed a statistically significant overall-survival benefit versus physician’s choice chemotherapy in previously treated TNBC, with no new safety signals at 29.4 months.